Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-870-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.95 million
Profitability
Miscellaneous
Employees73
OptionableOptionable
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) announced its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.12. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 31.73%. View Calithera Biosciences' Earnings History.
When is Calithera Biosciences' next earnings date?
What price target have analysts set for CALA?
2 brokers have issued 1 year price objectives for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they expect Calithera Biosciences' share price to reach $14.00 in the next year. This suggests a possible upside of 206.3% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.
What is the consensus analysts' recommendation for Calithera Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.
Has Calithera Biosciences been receiving favorable news coverage?
Media coverage about CALA stock has trended negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calithera Biosciences earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include Aurinia Pharmaceuticals (AUPH), Vectura Group (VEGPF), Kura Oncology (KURA), Ra Pharmaceuticals (RARX), CannTrust (CNTTF), ANI Pharmaceuticals (ANIP), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), ChemoCentryx (CCXI), Viking Therapeutics (VKTX), Karyopharm Therapeutics (KPTI), Aptinyx (APTX), Cara Therapeutics (CARA), ProQR Therapeutics (PRQR) and MacroGenics (MGNX).
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 64)
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 44)
- Dr. Keith Orford, Sr. VP of Clinical Devel. (Age 46)
- Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 44)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.03%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.
Which institutional investors are buying Calithera Biosciences stock?
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $4.57.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $163.18 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.
What is Calithera Biosciences' official website?
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
